MAVENIR
20.2.2024 08:01:34 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks, announces new developments on its OpenBeam™ massive MIMO (mMIMO) portfolio, powered by Qualcomm® QRU100 5G RAN platform, in continuation to previous years product launch update. Mavenir expands the OpenBeam™ portfolio by introducing the low-power next-generation 32TRX mMIMO variant along with a high-power 32TRX AAU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240219034877/en/
Mavenir OpenBeam massive MIMO 32TRX Active Antenna Unit. (Photo: Business Wire)
These next-generation mMIMO 32TRX Active Antenna Units (AAUs) introduce a new breed of open and interoperable radios that are green by design. OpenBeam™ mMIMO AAU delivers exceptional energy efficiency – resulting in one of the leanest mMIMO AAU footprints in the industry, offering substantial OpEx savings.
In addition to the current O-RAN 7.2b specification, the products are also engineered to support ULPI (Uplink Performance Improvement), allowing network operators to improve uplink performance of massive MIMO, minimize latency, and reduce fronthaul bandwidth, especially in urban settings where network capacity demand is high.
The portfolio consists of two discrete models that accelerate 5G mid-band rollouts:
- 32TRX AAU low power model: Offering one of the lowest footprints in the industry, the low power mMIMO AAU delivers 200W output power with 128 antenna elements at the lowest energy consumption. The solution is optimized for deployment in dense environments, driving faster installations and lower operational overheads.
- 32TRX AAU high power model: Mavenir’s high-performance mMIMO AAU capable of delivering 320W output power and offering 192 antenna elements. This platform supports larger instantaneous bandwidth, while the output power extends coverage, making it ideal for RAN sharing deployments.
The 32TRX AAU solutions deliver advanced energy-saving capabilities incorporating smart sleep-mode schemes that are activated during idle, low, and busy hour traffic. These automated capabilities can be further enhanced using AI/ML-based intelligence.
Paco Martin, Head of Open RAN at Vodafone Group: “We are pleased to see the broadening of Mavenir’s mMIMO portfolio with the addition of a low power, compact product fitting our single-operator and footprint-constrained sites, on top of the existing higher power leading solution. Further adoption of Qualcomm QRU100 5G RAN Platform keeps bringing high performance and power efficient Open RAN radios allowing us to deliver the best customer experience.”
BG Kumar, President, Access Networks, Platforms and MDE from Mavenir said: “With this continuing evolution and enhancement of our OpenBeam™ massive MIMO radio solutions, Mavenir is once again setting new standards in the industry for energy efficiency, sustainability and performance.”
“We are very pleased with this extension to Mavenir’s portfolio of high performing and power efficient Massive MIMO Radios, powered by Qualcomm QRU100 5G RAN Platform,” said Gerardo Giaretta, Vice President, Product Management, Qualcomm Technologies, Inc. “This is another great milestone in our ongoing collaboration with Mavenir, driving full-scale adoption of Open and Virtualized RAN.”
Mavenir’s OpenBeam™ full radio portfolio will be displayed at the upcoming Mobile World Congress in Barcelona, Feb 26-29, in Hall 2 Stand 2H60. For more on Mavenir’s presence at the show visit www.mavenir.com/mwc-2024
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 300+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
For more information, please visit www.mavenir.com
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240219034877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom